Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended		45 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash flows from operating activities:
Net loss	$ (4,779,000)	$ (1,988,000)	$ (26,126,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	95,000	73,000	853,000
Stock-based compensation expense	1,864,000	624,000	9,681,000
Liquidation preferences granted to founder			4,841,000
Derivative liability expense	1,683,000	154,000	1,741,000
Warrant amendment expense			734,000
Amortization of discount on a debt	90,000		90,000
Issuance of common stock to consultants			1,145,000
Gain on bargain purchase	(6,444,000)		(6,444,000)
Loss on extinguishment of debt			663,000
Decrease in stock buy-back liability			(150,000)
Changes in operating assets and liabilities, net of Merger:
(Increase) decrease in other current assets	(62,000)	2,000	(101,000)
Increase (decrease) in accounts payable	(1,097,000)	199,000	1,628,000
Increase (decrease) in due to related parties	(332,000)	320,000	314,000
Increase in other accrued liabilities	(833,000)	12,000	381,000
Increase in grants payable	2,000	8,000	522,000
Net cash used in operating activities	(3,369,000)	(595,000)	(10,342,000)
Cash flows from investing activities:
Cash acquired in Merger (1)			292,000
Change in restricted cash	112,000	(2,000)	202,000
Investment in Pre-Merger Immune Pharmaceuticals Inc.		(410,000)	(1,598,000)
Purchase of property and equipment	(20,000)		(62,000)
Purchase of intangible assets	(112,000)		(632,000)
Net cash used in investing activities	(20,000)	(412,000)	(1,798,000)
Cash flows from financing activities:
Proceeds from issuance of shares, net of issuance costs		915,000	8,008,000
Proceeds from issuance of Preferred C Stock, net of issuance costs of $180	10,171,000		10,171,000
Receipt of loans	269,000		392,000
Issuance of convertible loans			266,000
Repayment of loans	(86,000)		(183,000)
Proceeds received from deposits for future financing	(500,000)
Net cash provided by financing activities	9,854,000	915,000	18,654,000
Increase (decrease) in cash and cash equivalents	6,465,000	(93,000)	6,514,000
Cash and cash equivalents at beginning of period	49,000	95,000
Cash and cash equivalents at end of period	6,514,000	2,000	6,514,000
Supplemental disclosure of cash flow information:
Cash paid for interest	132,000		186,000
Cash paid for income taxes			7,000
Supplemental disclosure of non-cash financing activities:
Deemed dividend			(932,000)
Intangible assets acquired in non-monetary exchange			3,818,000
Assets Acquired [Member]
(1) Merger between Immune Pharmaceuticals Inc. and Immune Pharmaceuticals Ltd.:
Assets Acquired			377,000
Fair value of other Merger liabilities assumed			4,814,000
Fair value of investment and related party liability assumed			1,598,000
Fair value of deferred tax liability assumed			10,870,000
In Process Research and Development Acquired [Member]
(1) Merger between Immune Pharmaceuticals Inc. and Immune Pharmaceuticals Ltd.:
Assets Acquired			27,500,000
Senior Secured Term Loan Assumed [Member]
(1) Merger between Immune Pharmaceuticals Inc. and Immune Pharmaceuticals Ltd.:
Fair value of senior secured term loan assumed			$ 4,442,000